SynecorAlternative Names: RL 6893
Latest Information Update: 26 Apr 1995
At a glance
- Originator Aventis
- Class Antihypertensives
- Mechanism of Action ACE inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 26 Apr 1995 Discontinued-Preclinical for Hypertension in USA (Unknown route)